Key result
In spontaneously hypertensive rats, candesartan significantly decreased blood pressure and levels of circulating and vascular inflammatory markers compared to triple therapy (P<0.05).
Why the study?
Does candesartan reduce vascular and circulating inflammatory mediators in spontaneously hypertensive rats compared to standard triple therapy?
Population
Adult spontaneously hypertensive rats (SHR) and age-matched Wistar-Kyoto rats (WKY) as normotensive reference
Comparison
Candesartan (2 mg/kg/day) for 10 weeks vs Untreated SHR and SHR treated with…
Design
Preclinical
Follow-up
10 weeks
Authors
Loading...
Hypothesis-generating in hypertensive rat models; does not support practice change or human translation without clinical trials.
Does candesartan reduce vascular and circulating inflammatory mediators in spontaneously hypertensive rats compared to standard triple therapy?
p-value: p=<0.05
Candesartan reduces vascular and circulating inflammatory mediators in spontaneously hypertensive rats beyond its blood pressure-lowering effects, likely through downregulation of NF-kappaB and upregulation of IkappaB.
Sanz‐Rosa et al. (2004) studied Hypertension. Candesartan vs. Antihypertensive triple therapy (TT) or untreated SHR was evaluated on Aortic mRNA expression of IL-1beta, IL-6, and TNF-alpha and plasma levels (p=<0.05). In spontaneously hypertensive rats, candesartan significantly decreased blood pressure and levels of circulating and vascular inflammatory markers compared to triple therapy (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: